"Phosphorus Lowering Therapies (PLTs) – Why Patient Care Choice and Access Matters"

"AAKP HealthLine Innovator: Phosphorus Lowering Therapies (PLTs) – Why Patient Care Choice and Access Matters"

Despite advances in medical science during this Decade of the Kidney™, the journey for kidney patients remains challenging, marked by complex treatment regimens, ongoing health complications and serious unmet needs. This HealthLine Innovator webinar will shed light on critical gaps that persist in kidney patient care choice and access to new, innovative and FDA-approved solutions that are emerging to address these challenges.

One such area that demands our immediate attention is the management of hyperphosphatemia, a condition characterized by elevated phosphorus levels in the blood and managed through Phosphate Lowering Therapies (PLTs). Hyperphosphatemia is a common and serious issue for kidney patients, often leading to bone and cardiovascular complications if not effectively managed.

A new, FDA-approved treatment option is already making a difference for patients battling high phosphorus levels while also improving patient adherence and quality of life by reducing the pill burden associated with status quo phosphorus treatments like phosphate binders.

One question that will be raised and addressed in this webinar is why the Centers for Medicare and Medicaid Services (CMS) is planning to restrict patient and physician choice access to this new and safe FDA-approved treatment.



Moderator:
Jerome Bailey
Director of Patient Engagement and Advocacy
American Association of Kidney Patients


Speakers:
Barry H. Smith, MD, PhD
President
Dreyfus Health Policy and Research Center


Laura Williams, MD, MPH
Chief Medical Officer
Ardelyx


Richard Stacewicz
Home Hemodialysis Patient
AAKP Ambassador


Paul T. Conway
Chair of Policy and Global Affairs
American Association of Kidney Patients
Kidney Transplant Recipient



As the oldest and largest, independent kidney patient organization in the U.S. – AAKP is dedicated to improving the lives and long-term outcomes of kidney patients through education, advocacy, patient engagement, and the fostering of patient communities. AAKP fights for early disease detection and the appropriate diagnosis of rare/genetic conditions; increased kidney transplantation and pre-emptive transplantation; full patient choice of either in-center or home dialysis; protection of the patient/physician relationship; promotion of research and innovation including artificial implantable and wearable kidneys; and the elimination of barriers for patient access to available treatment options. Learn more at www.aakp.org.